GL1X · GenesisL1 explorer

MolNFT v1 · #80867 · protein

Structure of human leukotriene A4 hydrolase in complex with inhibitor SC57461A

3U9W · Leukotriene a-4 hydrolase: “Structure of human leukotriene A4 hydrolase in complex with inhibitor SC57461A”. X-ray diffraction, 4 ligands (28P, YB, ZN), 4 pockets (best druggability 0.85). MolNFT v1 #80867 on GenesisL1: 3D…

PDB
3U9W
Type
protein
Length
608 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Leukotriene a-4 hydrolase
EC
3.3.2.6
UniProt
P09960
Ligands
28P, YB, ZN, CL
Pockets
4 · best druggability 0.85

Structure

x-ray diffraction · 1 distinct chain · 44% helix, 23% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ALeukotriene a-4 hydrolase (EC 3.3.2.6)protein60844% helix, 23% strandP09960

Ligands and binding sites

  • 28P · N-[3-(4-benzylphenoxy)propyl]-N-methyl-beta-alanine · ligand · chains A
  • YB · Ytterbium (III) ion · metal · 8 copies · chains A
  • ZN · Zinc ion · metal · chains A
  • CL · Chloride ion · ion · 2 copies · chains A
  • IMD · Imidazole · additive · 3 copies · chains A
  • GOL · Glycerol · additive · chains A
  • ACT · Acetate ion · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
111160.850.8697IMD, 28P
22130.530.7728empty
31050.520.8319empty
41300.420.7627empty

Compared structures

  • 3U9W · Structure of human Leukotriene A4 hydrolase in complex with inhibitor sc57461A · the same entry in another collection · chain A against A, TM-score 1.00
  • P09960 · AlphaFold monomer V2.0 prediction for leukotriene a-4 hydrolase (P09960) · a predicted model of the same protein · chain A against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.